algeldrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4250	21645-51-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aluminum hydroxide algeldrate aluminum hydroxide hydrate aluminium hydroxide	A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Molecular weight: 78.00 Formula: AlH3O3 CLOGP: -1.75 LIPINSKI: None HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: ROTB: 0

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aluminum hydroxide
algeldrate
aluminum hydroxide hydrate
aluminium hydroxide

A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.

Molecular weight: 78.00
Formula: AlH3O3
CLOGP: -1.75
LIPINSKI: None
HAC: 3
HDO: 3
TPSA: 60.69
ALOGS:
ROTB: 0

Drug dosage:

Dose	Unit	Route
5	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1983	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Schizoaffective disorder	529.01	19.53	103	3929	3459	63481531
Drug level increased	343.57	19.53	104	3928	22632	63462358
Electrocardiogram QT prolonged	259.18	19.53	108	3924	59422	63425568
Drug interaction	166.48	19.53	128	3904	229003	63255987
Sinus rhythm	42.21	19.53	10	4022	846	63484144
Delirium	35.94	19.53	28	4004	50513	63434477
Acute myocardial infarction	27.74	19.53	20	4012	32104	63452886
Drug ineffective	25.16	19.53	18	4014	1044747	62440243
Hyponatraemia	24.86	19.53	33	3999	111867	63373123
Coma scale abnormal	24.54	19.53	10	4022	5143	63479847
Maternal drugs affecting foetus	24.37	19.53	10	4022	5232	63479758
Morbid thoughts	24.17	19.53	6	4026	617	63484373
Hypercapnia	24.03	19.53	10	4022	5421	63479569
Acute kidney injury	23.86	19.53	52	3980	263363	63221627
Erysipelas	23.47	19.53	11	4021	7894	63477096
Periventricular leukomalacia	20.71	19.53	4	4028	127	63484863
Agitation	20.50	19.53	22	4010	59735	63425255

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Mesothelioma	46.38	19.33	10	2803	435	34953683
Violence-related symptom	23.66	19.33	6	2807	530	34953588
IVth nerve paresis	19.91	19.33	3	2810	15	34954103
Exposure during pregnancy	19.75	19.33	11	2802	8923	34945195

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myocardial infarction	40.58	17.04	36	5070	77000	79662282
Violence-related symptom	33.18	17.04	8	5098	723	79738559
Hyponatraemia	26.97	17.04	44	5062	177804	79561478
General physical health deterioration	24.22	17.04	54	5052	275184	79464098
Morbid thoughts	22.62	17.04	6	5100	796	79738486
Hypercapnia	22.10	17.04	11	5095	8924	79730358
Mesothelioma	21.87	17.04	5	5101	359	79738923
Drug ineffective	21.08	17.04	23	5083	1080890	78658392
Cardio-respiratory arrest	20.88	17.04	30	5076	108480	79630802
Blood phosphorus increased	20.58	17.04	11	5095	10336	79728946
Erysipelas	20.09	17.04	11	5095	10839	79728443
Appendicolith	19.61	17.04	10	5096	8541	79730741
Coma scale abnormal	19.47	17.04	10	5096	8668	79730614
Cerebrovascular accident	19.05	17.04	35	5071	155257	79584025
Vomiting	18.61	17.04	88	5018	665740	79073542
Acute kidney injury	18.61	17.04	74	5032	519330	79219952
Myeloid maturation arrest	17.78	17.04	3	5103	43	79739239
Seizure	17.67	17.04	38	5068	188796	79550486
Anal incontinence	17.18	17.04	12	5094	18156	79721126
Diabetic foot	17.07	17.04	7	5099	3625	79735657

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02AB01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
ATC	A02AB02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Aluminium compounds
MeSH PA	D000276	Adjuvants, Immunologic
MeSH PA	D000863	Antacids
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D007155	Immunologic Factors
CHEBI has role	CHEBI:65265	antacids
CHEBI has role	CHEBI:79314	flame retardants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Heartburn	indication	16331000
Duodenal ulcer disease	indication	51868009	DOID:1724
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Gastric ulcer	indication	397825006	DOID:10808
Gastric Hypersecretory Conditions	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.51	acidic
pKa2	4.99	acidic
pKa3	5.47	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018607	VUID
N0000146920	NUI
D02807	KEGG_DRUG
4017984	VANDF
4018607	VANDF
4019302	VANDF
C0002371	UMLSCUI
CHEBI:33130	CHEBI
CHEMBL3833310	ChEMBL_ID
CHEMBL1200706	ChEMBL_ID
D000536	MESH_DESCRIPTOR_UI
1945	INN_ID
03J11K103C	UNII
DB06723	DRUGBANK_ID
612	RXNORM
4159	MMSL
5582	MMSL
7537	MMSL
d00978	MMSL
001123	NDDF
007943	NDDF
273944007	SNOMEDCT_US
725733004	SNOMEDCT_US
768557001	SNOMEDCT_US
80399002	SNOMEDCT_US
1330-44-5	SECONDARY_CAS_RN
6328660	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Good Sense antacid	HUMAN OTC DRUG LABEL	3	0113-0340	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidRegular Strength	HUMAN OTC DRUG LABEL	3	0113-0357	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Good Sense AntacidMaximum Strength	HUMAN OTC DRUG LABEL	3	0113-0588	SUSPENSION	800 mg	ORAL	OTC monograph final	13 sections
good sense antacid	HUMAN OTC DRUG LABEL	3	0113-0851	SUSPENSION	400 mg	ORAL	OTC monograph final	13 sections
Mag-AL Liquid	HUMAN OTC DRUG LABEL	2	0121-1760	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Liquid	HUMAN OTC DRUG LABEL	2	0121-1760	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Plus	HUMAN OTC DRUG LABEL	3	0121-1761	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Plus	HUMAN OTC DRUG LABEL	3	0121-1761	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL Plus	HUMAN OTC DRUG LABEL	3	0121-1761	SUSPENSION	200 mg	ORAL	OTC monograph final	14 sections
Mag-AL PlusXS	HUMAN OTC DRUG LABEL	3	0121-1762	SUSPENSION	400 mg	ORAL	OTC monograph final	15 sections
Mag-AL PlusXS	HUMAN OTC DRUG LABEL	3	0121-1762	SUSPENSION	400 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0094	LIQUID	95 mg	ORAL	OTC monograph final	13 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0095	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
GavisconRegular Strength	HUMAN OTC DRUG LABEL	2	0135-0096	TABLET, CHEWABLE	80 mg	ORAL	NDA	15 sections
GavisconRegular Strength	HUMAN OTC DRUG LABEL	2	0135-0096	TABLET, CHEWABLE	80 mg	ORAL	NDA	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0574	LIQUID	254 mg	ORAL	OTC monograph final	13 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINAL	14 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINAL	14 sections
Antacid Mint	HUMAN OTC DRUG LABEL	3	0363-0432	SUSPENSION	200 mg	ORAL	OTC MONOGRAPH FINAL	14 sections
Antacid antigasMaximum Strength	HUMAN OTC DRUG LABEL	3	0363-0528	LIQUID	800 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	12 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	160 mg	ORAL	OTC monograph final	12 sections
ADVANCED REGULAR STRENGTH ANTACID	HUMAN OTC DRUG LABEL	3	0363-1639	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
ADVANCED REGULAR STRENGTH ANTACID	HUMAN OTC DRUG LABEL	3	0363-1639	SUSPENSION	200 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-1691	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections
MAXIMUM STRENGTH ANTACID ANTIGAS	HUMAN OTC DRUG LABEL	3	0363-1691	SUSPENSION	400 mg	ORAL	OTC monograph final	10 sections